Analysts await Chimerix, Inc. (NASDAQ:CMRX) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.67 EPS, down 19.4% or $0.13 from last year’s $-0.54 per share.

At the moment 10 analysts are watching Chimerix, Inc. (NASDAQ:CMRX), 0 rate it “Buy”, 1 “Outperform”, 8 “Underperform”, 1 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 6 analysts have a mean sales target of 2.60 million. For the quarter ending Sep-16, 6 analysts have a mean sales target of 2.55 million whilst for the year ending Dec-16, 8 analysts have a mean target of 9.28 million.

In terms of earnings per share, 9 analysts have a -0.58 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 9 analysts have a -0.53 EPS mean target and for the quarter ending Sep-16 there are 10 estimates of -2.27 EPS.

The biggest institutional shareholders in Chimerix, Inc. include Fidelity Management and Research Company which owns 7 million shares in the company valued at $61.95 million. Sanderling Venture Partners VI, L.P. is the second biggest holder with 3 million shares currently valued at 124.81 million whilst Bridger Management Llc has 3 million shares valued at 26.56 million.

Total shares held by institutions as of the most recent company filings are 42,064,678 with a reported 3,847,762 bought and 8,983,697 sold. These holdings make up 91.1% of the company’s outstanding shares.

Currently insiders hold 475,945 shares in the business which makes up 1.03% of shares. The biggest holder currently is Dr. Ernest Mario,PhD who owns 296,440 shares (0.64% of those outstanding), whilst Dr. M. Michelle Berrey,M.D.,M.P.H. holds 145,633 (0.32% of shares outstanding) and Dr. Michael D. Rogers,PhD holds 21,630 (0.05% of shares outstanding).

The stock decreased 2.29% or $0.12 during the last trading session, hitting $6.74. Chimerix, Inc. (NASDAQ:CMRX) has fallen 488.43% over the past 6 months and is downtrending.